OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara explains how the company managed to prove their commercial model with a solid foundation to begin 2021 in a strong position.
He sets out the agenda for 2021 which is to 'focus on the next generation of products'.
The company's key products, in which there are now 78 deals ongoing are weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).